



## Health & Human Services Committee

### “Clearing the Air about Electronic Cigarettes”

Tuesday, Aug. 4, 4:00-5:00 pm. WC611-614

**Summary:** Many policy questions have been raised about electronic cigarettes and other vapor products. While states have largely banned their sale to minors, questions remain about federal regulation and about their relative health risks compared with traditional cigarettes.

**Moderator:** Senator Patricia Miller, Indiana

**Panelist:** Karmen Hanson, Program Manager, NCSL

**Panelist:** Cynthia Hallett, Americans For Nonsmokers' Rights, California

**Panelist:** Jack Henningfield, Pinney Associates, Maryland

**Karmen Hanson, MA** is a program manager with NCSL’s Health Program. She is a nationally recognized health policy expert with more than 20 years of legislative and local government policy experience. Starting with NCSL in 2001, she has worked on numerous projects and has managed NCSL’s tobacco work for over seven years. She has authored several articles and briefs about tobacco and alternative nicotine policies. Her other areas of policy expertise include state marijuana/cannabis programs, cancer, pharmaceuticals, mental health, substance abuse and insurance issues.

**Cynthia Hallett, MPH** is the Executive Director of Americans for Nonsmokers’ Rights (ANR) and the ANR Foundation where she’s worked since 1997. Cynthia’s career in tobacco control began in 1989 at the Los Angeles County Department of Health Services Tobacco Control Program. Over the last 25 years, she has spearheaded successful smokefree air campaigns, tracked and exposed tobacco industry interference, served as a media spokesperson and keynote lecturer, as well as provided technical assistance, training, and strategic guidance in support of smokefree air and public health policy efforts across the U.S. and internationally. Cynthia’s early training was in cancer control and prevention, and she has worked at the National Cancer Institute and the UCLA Comprehensive Cancer Center. She received her Bachelor of Arts and Master of Public Health degrees from University of California, Los Angeles. She has served as a Governing Councilor, and is the past Chair for the Alcohol, Tobacco, and Other Drugs (ATOD) Section of the American Public Health Association, is a Board Member of the Cigarette Butts Pollution Project, a member of the UCSF/Legacy Library Advisory Board and the Global Smokefree Partnership, and served on the Steering Committee for Communities Putting Prevention to Work project.

**Jack Henningfield, PhD** is Vice President, Research, and Health Policy at PinneyAssociates, and Adjunct Professor of Behavioral Biology, in the Department of Psychiatry and Behavioral Sciences at The Johns Hopkins University School of Medicine. He served on FDA’s first Tobacco Products Scientific Advisory Committee (TPSAC) from 2010 to 2011, and the World Health Organization’s first Tobacco Regulation Study Group and its predecessor the Scientific Advisory Committee on Tobacco Regulation from 2000 to 2014. Before PinneyAssociates, he headed the Clinical Pharmacology Branch of the National Institute on Drug Abuse (NIDA), as well as the Biology of Dependence and Abuse Potential Assessment laboratory. Since 1981 he has advised the FDA and CDC on matters concerning abuse and dependence liability of a broad range of drugs and regulatory challenges including tobacco and nicotine products and FDA’s proposed Tobacco Regulation. In addition, Dr. Henningfield was an editor of the 1988 Surgeon General Report on Nicotine Addiction and a contributor to the 2014 50<sup>th</sup> Anniversary Surgeon General Report. He has published more than 400 scientific articles, books and monographs, and is recipient of numerous awards from federal agencies and scientific organizations. For decades his professional passion has been to serve public health through science-guided policy. Through PinneyAssociates he consults to pharmaceutical companies on the development and regulation of more effective, safer, and less addictive medicines. He had consulted for NJOY in 2014 on their vapor products, and since February 2015 to Reynolds American on their vapor products and to its pharmaceutical subsidiary, Nicovum, which markets an FDA-approved nicotine gum for smoking cessation. See [www.PinneyAssociates.com](http://www.PinneyAssociates.com) for more information.